Citius Oncology Analyst Price Targets - Benzinga

Citius Oncology Inc

CTORNASDAQ

Trade with Public

Trade with Public

$0.7206

-0.0294-3.92%

마지막 업데이트: Aug 25, 10:15 AM

개요 뉴스 실적 전망 이벤트목표가재무 심리 비교 주식 보고서

Citius Oncology Analyst Price Targets

Wall Street analyst price targets and consensus rating for Citius Oncology (CTOR).

Price Target Range — 3 Quarters

Analyst Consensus — 2 Analysts

2Buy

Consensus RatingBuy# Analysts2Avg. Consensus PT$6Upside to Avg. PT+732.6%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 23, 2025	Maxim Group	Michael Okunewitch	Upgrade	Hold→Buy	$6
May 23, 2025	Maxim Group	Michael Okunewitch	Downgrade	Buy→Hold	—
Nov 27, 2024	Maxim Group	Michael Okunewitch	Initiate	Buy	$3
Aug 13, 2024	EF Hutton	Jason Kolbert	Maintained	Buy	$6

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Maxim Group Upgrades Citius Oncology to Buy, Announces $6 Price Target

Maxim Group analyst Michael Okunewitch upgrades Citius Oncology (NASDAQ:CTOR) from Hold to Buy and announces $6 price target.

Benzinga Newsdesk

This Commercial Metals Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday

Avi Kapoor

This Deckers Outdoor Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday

Avi Kapoor

PRO
Maxim Group Downgrades Citius Oncology to Hold

Maxim Group analyst Michael Okunewitch downgrades Citius Oncology (NASDAQ:CTOR) from Buy to Hold.

Benzinga Newsdesk

PRO
Maxim Group Initiates Coverage On Citius Oncology with Buy Rating, Announces Price Target of $3

Maxim Group analyst Michael Okunewitch initiates coverage on Citius Oncology (NASDAQ:CTOR) with a Buy rating and announces Price Target of $3.

Benzinga Newsdesk

PRO
EF Hutton Maintains Buy on Citius Oncology, Maintains $6 Price Target

EF Hutton analyst Jason Kolbert maintains Citius Oncology (NASDAQ:CTOR) with a Buy and maintains $6 price target.

Benzinga Newsdesk